trader_ron
6月前
Dallas Texas December 11, 2025 Right on Brands (OTCID Current)
This strategic shift involves focusing on the development of proprietary, innovative
products to meet the wellness needs of consumers today. As the shift occurs, the
Company will begin withdrawing from THC related products.
The Company's initial foray is a medical polymer primarily derived from hemp oil which
acts as a safe, bio-absorbable wound dressing and artificial skin. It employs a
magnesium based cross linking system enhanced with anhydride cross link and allatoin.
Specifically formulated for wound coverage, protection and support of the natural
healing process, this product has significant potential. Right On Brands will be filing a
patent application prior to year end.
The Company also has several other proprietary products completed and in formulation
to address pain, insomnia and podiatric neuropathy issues common in the US
population.
Smart move Jerry
trader_ron
2年前
$RTON Right On Brands, Inc. is a Texas based consumer goods company specializing in brand development of hemp based products for health conscious individuals. Right On Brands consists of two operating segments: ENDO Brands and ENDO Dispensary and Wellness.. ENDO Brands develops hemp infused products such as gummies, vapes, edibles and which are engineered to deliver optimal bioavailability and nutrients to the body. From Tinctures to Gummies to Roll-ons, Premium PreRolls and Top Shelf Flower our premium products are designed to give you a premium experience at a reasonable cost. Thru our Right On Med Center telemedicine we will sell weight loss, sexual Wellness, Peptides, NAD+ and Testosterone. We aim to be a true Health and Wellness store, not just another CBD company.
https://www.dropbox.com/scl/fi/6esybrr34yk9y577pi7nm/Right-On-Brands-Inc.-2.pdf?rlkey=hnxyw3p0y2nhmsw2mqaf6mo26&st=rl9p42bu&dl=0
trader_ron
2年前
$RTON Market Analysis out by Globe Small Cap Research
A $1.00 price target has been established on shares of Right One Brands based on entry into the ultra-rapidly growing telemedicine and wellness sector and on the well-established growth being experienced in the THC-A hemp consumer product segment. § RTON is implementing a plan to install telemedicine portals in all its retail locations. With booming sales of weight loss peptides, such as Ozempic, and testosterone replacement therapy reaching the mainstream male population, we believe the Company’s strategic plans are well placed. A new video explaining the updated telemedicine entry can be viewed at . § This Company deserves consideration by risk-averse micro and small cap-oriented investors. The Company is operating in hot market sectors where growth opportunities are stellar. § The Company, with its strategic expansion plans, recently opened its 13th location in Texas and aims to have 25 locations in operation by year-end, demonstrating a clear path for future growth. § The share structure is particularly common shareholder friendly – low count and limited convertible debt. § The THCA product market, legal under the 2018 Federal Farm Bill, is creating huge opportunities for both retailers and investors. We consider this sector to still be below the radar of most investors. Exposure is likely to boost share prices for all participants. § A solid management team with considerable experience and diverse backgrounds in hemp, financial management, and operations. § In our opinion, this Company is worthy of active consideration and ongoing following for developments. https://www.dropbox.com/scl/fi/zhcr3gpffi6spxorv8et3/RTON-061024B.pdf?rlkey=nr1108l7jcy89i8gc1ae88u5e&st=f67bgyh3&dl=0
trader_ron
2年前
$RTON Market Analysis out by Globe Small Cap Research
A $1.00 price target has been established on shares of Right One Brands based on entry into the ultra-rapidly growing telemedicine and wellness sector and on the well-established growth being experienced in the THC-A hemp consumer product segment. § RTON is implementing a plan to install telemedicine portals in all its retail locations. With booming sales of weight loss peptides, such as Ozempic, and testosterone replacement therapy reaching the mainstream male population, we believe the Company’s strategic plans are well placed. A new video explaining the updated telemedicine entry can be viewed at . § This Company deserves consideration by risk-averse micro and small cap-oriented investors. The Company is operating in hot market sectors where growth opportunities are stellar. § The Company, with its strategic expansion plans, recently opened its 13th location in Texas and aims to have 25 locations in operation by year-end, demonstrating a clear path for future growth. § The share structure is particularly common shareholder friendly – low count and limited convertible debt. § The THCA product market, legal under the 2018 Federal Farm Bill, is creating huge opportunities for both retailers and investors. We consider this sector to still be below the radar of most investors. Exposure is likely to boost share prices for all participants. § A solid management team with considerable experience and diverse backgrounds in hemp, financial management, and operations. § In our opinion, this Company is worthy of active consideration and ongoing following for developments. https://www.dropbox.com/scl/fi/zhcr3gpffi6spxorv8et3/RTON-061024B.pdf?rlkey=nr1108l7jcy89i8gc1ae88u5e&st=f67bgyh3&dl=0